Moderna, the biotech company behind one of the original mRNA COVID-19 vaccines, is undergoing an AI-powered workplace transformation. In partnership with OpenAI, Moderna has created thousands of ...

Moderna stock hasn’t been a favorite of investors since demand for its coronavirus vaccine started to drop. But this biotech is showing the market that it has what it takes to produce multiple ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market. MRNA's Court Victory A German court ruled that BioNTech (BNTX) and ...

Moderna shares tumbled Monday after the company cut its 2025 revenue forecast by $1 billion. The company expects much of its revenue to be realized in the back half of the year from its Covid-19 ...

Moderna has vowed to cut R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

Shares of Moderna MRNA rose 3% on Wednesday after management announced positive clinical updates at its Vaccines Day Event, highlighting its pipeline progress. While the company provided an update ...

Moderna's sales plunged in 2023 as demand for its COVID vaccine has been diminishing. The company has multiple products in its pipeline that could be key parts of its business in five years ...

Moderna should hit the lower end of its sales target for this year as it only needs to tap a small portion of the private market with its COVID vaccine to reach that goal, according to industry ...

Moderna has joined forces with a local pharmaceutical company to manufacture mRNA vaccines in Cambridge, Ont., the province announced on Thursday. A release says the company will use Novocol ...

Stéphane Bancel, chief executive of Moderna, had a good year in 2022, exercising stock options that netted him nearly $393 million. The company decided his pay wasn’t good enough. The Cambridge ...

Vaccine maker Moderna and computing giant IBM are teaming up to explore how quantum computing and artificial intelligence can develop future mRNA medicines, both companies announced on Thursday ...

BOSTON, April 11 (Reuters) - Moderna Inc (MRNA.O), opens new tab said on Tuesday its experimental flu vaccine did not meet the criteria for "early success" in a late-stage trial, and its shares ...